FIELD: urology. SUBSTANCE: method designed for treating benign prostate hyperplasia and consists in administering dextrorotatory isomer of doxasosine or its pharmaceutically acceptable salt containing less than 10% of levorotatory doxasosine isomer. EFFECT: decreased or eliminated hypotensive effects caused by racemic doxasosine. 5 cl, 2 ex
Authors
Dates
1999-10-10—Published
1993-11-02—Filed